Patient: Description of condition (onset, main symptoms, hospital visited, etc.): August 10, 2011, invasive ductal carcinoma, moderately differentiated, with high-grade ductal carcinoma in situ, fibrosis and inflammatory cell reaction around the carcinoma, the mass did not involve the nipple, no carcinoma was seen at the bottom cut edge of the surgery, metastatic carcinoma was seen in the axillary lymph nodes (1/8) Immunochemistry: ER (++) CrebB-2 (++), Ki-67 (20%+), p53(+), E-Cadherin(+++), EMA(++), CD34(vascular+), I was seen in Beijing hospital, 2 courses of chemotherapy, is the value of immunochemistry ideal? What do I need to pay attention to? Zhang Shurong, Oncology Center of Beijing Tongren Hospital: The immunohistochemical test results of tumor tissues only reflect certain indicators of tumor characteristics, some reflect the sensitivity of drug therapy, some reflect its proliferation ability, so it is not ideal or unsatisfactory to talk about. It is recommended to test whether Her-2 gene is amplified or overexpressed to decide whether to use targeted therapy. Endocrine therapy is recommended for more than 5 years after the end of chemotherapy.